Aaron Mansfield, MD
Medical Oncology · Rochester, MNNPI 1437278959
Payments from drug & device makers
Across 279 payments — averaging $18,138 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$957K
- Blueprint Medicines Corporation$821K
- Pfizer$708K
- AbbVie$427K
- Genentech, Inc.$426K
- Novartis$391K
- plus $1.3M from 16 others
Across 14 payments — averaging $2166.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$21K
- F. Hoffmann-la Roche AG$10K
- AbbVie$92
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 64 | $956,689 |
| Blueprint Medicines Corporation | 22 | $820,769 |
| Pfizer | 2 | $707,836 |
| AbbVie | 56 | $426,933 |
| Genentech, Inc. | 49 | $426,475 |
| Novartis | 5 | $390,809 |
| Amgen | 2 | $362,149 |
| E.r. Squibb & Sons, L.L.C. | 4 | $333,181 |
| Hoffmann-la Roche Limited | 13 | $176,217 |
| Merck | 26 | $155,941 |
| AstraZeneca | 2 | $132,790 |
| Incyte Corporation | 3 | $84,270 |
| EMD Serono, Inc. | 7 | $49,540 |
| F. Hoffmann-la Roche AG | 9 | $10,427 |
| Gilead | 3 | $6,100 |
| Genentech USA, Inc. | 5 | $5,866 |
| Immunocore Limited | 1 | $5,000 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $3,300 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $3,156 |
| Johnson & Johnson | 1 | $1,905 |
| Janssen Scientific Affairs, LLC | 1 | $1,010 |
| Bristol Myers Squibb | 1 | $21 |
How this compares
$5,060,384 in reported general payments places this provider in the 85th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Rochester
- Evanthia GalanisRochester$72.3M
- Frank SinicropeRochester$10.3M
- Harry YoonRochester$10.2M
- Konstantinos LeventakosRochester$9.6M
- Matthew BlockRochester$8.1M
- Keith BibleRochester$7.5M
- Jian CampianRochester$7.3M
- Katharine PriceRochester$7M
- Robert McWilliamsRochester$6.3M
- Elisabeth HeathRochester$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.